Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis

International Journal of Antimicrobial Agents

Volumn 46, Issue 3, 2015, Pages 332-337

  Dijkstra, J A ^a   Van Altena, R ^a   Akkerman, O W ^a   De Lange, W C M ^a   Proost, J H ^b   Van Der Werf, T S ^a   Kosterink, J G W ^a,b   Alffenaar, J W C ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Amikacin; Kanamycin; Limited sampling; Pharmacokinetic model; Pharmacokinetics; Tuberculosis

Indexed keywords

AMIKACIN; KANAMYCIN; TUBERCULOSTATIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG MONITORING; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; POPULATION MODEL; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUME OF DISTRIBUTION; BIOSTATISTICS; LABORATORY DIAGNOSIS; PROCEDURES; STATISTICAL MODEL; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

ADULT; AMIKACIN; ANTITUBERCULAR AGENTS; BIOSTATISTICS; DRUG MONITORING; FEMALE; HUMANS; KANAMYCIN; MALE; MODELS, STATISTICAL; RETROSPECTIVE STUDIES; SPECIMEN HANDLING; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84940451078     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2015.06.008     Document Type: Article

References (32)

1. A. Zumla, M. Raviglione, R. Hafner, and C.F. von Reyn Tuberculosis N Engl J Med 368 2013 745 755
2. World Health Organization Global tuberculosis report 2014 2014 World Health Organization Geneva, Switzerland
3. E.W. Orenstein, S. Basu, N.S. Shah, J.R. Andrews, G.H. Friedland, A.P. Moll, and et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis Lancet Infect Dis 9 2009 153 161
4. World Health Organization Annex 2. Weight-based dosing of drugs for adults. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008 WHO Geneva, Switzerland p. 20
5. P. Jureen, K. Angeby, E. Sturegard, E. Chryssanthou, C.G. Giske, J. Werngren, and et al. Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections J Clin Microbiol 48 2010 1853 1858
6. E.J. Begg, M.L. Barclay, and S.B. Duffull A suggested approach to once-daily aminoglycoside dosing Br J Clin Pharmacol 39 1995 605 609
7. M. Zhu, W.J. Burman, G.S. Jaresko, S.E. Berning, R.W. Jelliffe, and C.A. Peloquin Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis Pharmacotherapy 21 2001 1037 1045
8. C.A. Peloquin, S.E. Berning, A.T. Nitta, P.M. Simone, M. Goble, G.A. Huitt, and et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases Clin Infect Dis 38 2004 1538 1544
9. P. de Jager, and R. van Altena Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis Int J Tuberc Lung Dis 6 2002 622 627
10. G. Perletti, A. Vral, M.C. Patrosso, E. Marras, I. Ceriani, P. Willems, and et al. Prevention and modulation of aminoglycoside ototoxicity Mol Med Rep 1 2008 3 13 [Review]
11. A. Beaubien New findings relate aminoglycoside ototoxicity to cumulative plasma or perilymph AUC Infect Dis Newsl 1992 11
12. M.J. Rybak, B.J. Abate, S.L. Kang, M.J. Ruffing, S.A. Lerner, and G.L. Drusano Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity Antimicrob Agents Chemother 43 1999 1549 1555
13. A.R. Beaubien, E. Ormsby, A. Bayne, K. Carrier, G. Crossfield, M. Downes, and et al. Evidence that amikacin ototoxicity is related to total perilymph area under the concentration-time curve regardless of concentration Antimicrob Agents Chemother 35 1991 1070 1074
14. R. van Altena, G. de Vries, C.H. Haar, W.C. de Lange, C. Magis-Escurra, S. van den Hof, and et al. Highly successful treatment outcome of multidrug-resistant tuberculosis in The Netherlands, 2000-2009 Int J Tuberc Lung Dis 19 2015 406 412
15. J.W. Alffenaar Dried blood spot analysis combined with limited sampling models can advance therapeutic drug monitoring of tuberculosis drugs J Infect Dis 205 2012 1765 1766 [author reply 1766]
16. J.A. Dijkstra, M.G. Sturkenboom, K. Hateren, R.A. Koster, B. Greijdanus, and J.W. Alffenaar Quantification of amikacin and kanamycin in serum using a simple and validated LC-MS/MS method Bioanalysis 6 2014 2125 2133
17. US Department of Health and Human Services, Food and Drug Administration Guidance for industry, bioanalytical method validation 2001 Center for Drug Evaluation and Research Rockville, MD
18. A. Fuchs, C. Csajka, Y. Thoma, T. Buclin, and N. Widmer Benchmarking therapeutic drug monitoring software: a review of available computer tools Clin Pharmacokinet 52 2013 9 22
19. D. Xuan, J.F. Lu, D.P. Nicolau, and C.H. Nightingale Population pharmacokinetics of tobramycin in hospitalized patients receiving once-daily dosing regimen Int J Antimicrob Agents 15 2000 185 191
20. J.H. Proost, and D.J. Eleveld Performance of an iterative two-stage Bayesian technique for population pharmacokinetic analysis of rich data sets Pharm Res 23 2006 2748 2759
21. J.W. Alffenaar, J.G. Kosterink, R. van Altena, T.S. van der Werf, D.R. Uges, and J.H. Proost Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis Ther Drug Monit 32 2010 97 101
22. A.D. Pranger, J.G. Kosterink, R. van Altena, R.E. Aarnoutse, T.S. van der Werf, D.R. Uges, and et al. Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis Ther Drug Monit 33 2011 350 354
23. Y. Wang, P.R. Jadhav, M. Lala, and J.V. Gobburu Clarification on precision criteria to derive sample size when designing pediatric pharmacokinetic studies J Clin Pharmacol 52 2012 1601 1606
24. M. Tod, O. Lortholary, D. Seytre, R. Semaoun, B. Uzzan, L. Guillevin, and et al. Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults Antimicrob Agents Chemother 42 1998 849 856
25. R. Galvez, C. Luengo, R. Cornejo, J. Kosche, C. Romero, E. Tobar, and et al. Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity Int J Antimicrob Agents 38 2011 146 151
26. R. Garraffo, H.B. Drugeon, P. Dellamonica, E. Bernard, and P. Lapalus Determination of optimal dosage regimen for amikacin in healthy volunteers by study of pharmacokinetics and bactericidal activity Antimicrob Agents Chemother 34 1990 614 621
27. T. Gumbo, A. Louie, M.R. Deziel, L.M. Parsons, M. Salfinger, and G.L. Drusano Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling J Infect Dis 190 2004 1642 1651
28. M. Bernabeu-Wittel, C. Pichardo, A. García-Curiel, M.E. Pachón-Ibáñez, J. Ibáñez-Martínez, M.E. Jiménez-Mejías, and et al. Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia Clin Microbiol Infect 11 2005 319 325
29. E. Nuermberger, and J. Grosset Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections Eur J Clin Microbiol Infect Dis 23 2004 243 255
30. C. Lange, I. Abubakar, J.W. Alffenaar, G. Bothamley, J.A. Caminero, A.C. Carvalho, and et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement Eur Respir J 44 2014 23 63
31. G. Sotgiu, J.W. Alffenaar, R. Centis, L. D'Ambrosio, A. Spanevello, A. Piana, and et al. Therapeutic drug monitoring: how to improve drug dosage and patient safety in tuberculosis treatment Int J Infect Dis 32 2015 101 104
32. C. Magis-Escurra, H.M. Later-Nijland, J.W. Alffenaar, J. Broeders, D.M. Burger, R. van Crevel, and et al. Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin Int J Antimicrob Agents 44 2014 229 234